A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as
determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and to
describe the safety profile of darbepoetin alfa in patients with MDS. The secondary objective
is to assess bone marrow progenitor BFU-E growth before and after treatment with darbepoetin
alfa.